CG Oncology Stock (NASDAQ:CGON)

Forecast Revenue Ownership Financials Chart

Previous Close

$54.92

52W Range

$23.65 - $75.50

50D Avg

$65.23

200D Avg

$51.04

Market Cap

$5.08B

Avg Vol (3M)

$1.12M

Beta

0.31

Div Yield

CGON Company Profile

CG Oncology Inc. is a biotechnology company in the clinical development stage, committed to advancing and bringing to market an innovative, bladder-sparing core treatment for individuals diagnosed with bladder cancer. Their principal drug candidate, cretostimogene, is presently undergoing clinical evaluation. Its initial focus is on providing a therapeutic option for patients suffering from high-risk Non-Muscle Invasive Bladder Cancer who have not responded to Bacillus Calmette Guerin (BCG) therapy, which represents the established standard of care for this particular severe form of NMIBC.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

113

IPO Date

Jan 25, 2024

Website

CGON Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Dec 25
License And Collaboration Revenue	$806.00K

Fiscal year ends in Dec 25 | Currency in USD

CGON Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	$4.04M	$1.14M	$204.00K
Operating Income	$-190.77M	$-114.67M	$-55.45M
Net Income	$-161.00M	$-88.04M	$-48.61M
EBITDA	$-159.55M	$-114.63M	$-55.43M
Basic EPS	$-2.08	$-1.41	$-1.02
Diluted EPS	$-2.08	$-1.41	$-1.02

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
IRON	Disc Medicine, Inc.
AAPG	Ascentage Pharma Group International
TARS	Tarsus Pharmaceuticals, Inc.
TVTX	Travere Therapeutics, Inc.
RARE	Ultragenyx Pharmaceutical Inc.
CELC	Celcuity Inc.
XENE	Xenon Pharmaceuticals Inc.
LEGN	Legend Biotech Corporation
CNTA	Centessa Pharmaceuticals plc
APGE	Apogee Therapeutics, Inc.